Volitionrx Stock Earnings Reports

Volition reported Q1 2026 revenue of ~$1.0M (vs. ~$0.2M a year ago), driven largely by a $0.7M deferred revenue recognition related to the Nu.Q Vet / Heska agreement. Operating expenses were $6.3M and operating loss was modestly improved year-over-year. Cash at quarter end was ~$3.1M, boosted by ~$5.4M net ATM proceeds and ~$1.9M from a convertible note, plus continued non-dilutive support (Walloon Region and others) bringing total non-dilutive funding to >$25M to date. Management reiterated that revenues remain lumpy and they will not provide 2026 revenue guidance. Key commercial and scientific progress across all product pillars: Nu.Q Vet—automation validation with Fujifilm Vet Systems in Japan and a submitted feline lymphoma manuscript that, upon publication, should trigger a $5M milestone; Nu.Q NETs—Mayo Clinic trauma data showing markedly elevated nucleosome levels linked to complications (including VTE), DETECSEPS sepsis study on track with recruitment expected in Q3, and successful finger‑prick lateral‑flow detection of nucleosomes; Nu.Q Discover—expanded collaborations (~100 clients), a new rNuQ webshop for recombinant nucleosomes; Nu.Q Cancer/Nu.Q Lung—clinical validation and reimbursement submission activity in France with potential clinical use later this year; Capture‑Seq—reported a potentially transformative method to generate >99% pure tumor‑derived ctDNA and blinded validation showing >95% detection of stage 1–2 cancers in a small cohort. Management is actively pursuing licensing deals with large diagnostics and liquid‑biopsy companies (discussions with a dozen+ potential partners at various stages). Cost reduction measures and further operating expense control are ongoing. Major near‑term catalysts: publication of the feline paper (milestone $ payment), progress on reimbursement/IVDR activities in France, DETECSEPS enrollment, further Capture‑Seq validation and licensing announcements.